Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach
Antresa Jose, Abul Bashar Mohammad Kamrul-Hasan, Cornelius J Fernandez, Joseph M Pappachan · 2026
Read Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approach by Antresa Jose, Abul Bashar Mohammad Kamrul-Hasan, Cornelius J Fernandez, Joseph M Pappachan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13491226.txt.
Description
Antresa Jose and colleagues argue, in an opinion review from twenty twenty-six, for adding the drug finerenone to the standard pair of medicines for diabetic kidney disease. Diabetes is now the leading cause of chronic kidney disease worldwide, and protein leaking into urine is its earliest sign and a strong risk marker. Trials have shown finerenone, a selective hormone-blocking drug, cuts kidney and heart events in long-standing type two diabetes. Another drug class that blocks sugar reabsorption in the kidney also protects it, by a different route.
Because the two classes act independently, the authors contend that combining them on top of blood pressure drugs that protect the kidney should beat either alone. The piece reviews current evidence for this layered, disease-modifying strategy and frames protein reduction as the practical target clinicians can track.
Catalog record
| CREATOR | Antresa Jose, Abul Bashar Mohammad Kamrul-Hasan, Cornelius J Fernandez, Joseph M Pappachan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |